

## PRESS RELEASE

# Piramal Pharma Solutions Announces Winner of its September 2022 Award for Excellence in Patient Centricity

- *Pithampur, India site's Patient Awareness Council wins the Award*
- *Site PAC recognized for its program to spread the culture of Patient Centricity not only across the site, but with local and regional external partners and stakeholders*
- *The Excellence Award recognizes the hands-on application of Patient Centricity and a focus on helping to reduce the burden of disease on patients*

**Mumbai, India | November 2, 2022:** Piramal Pharma Limited's Pharma Solutions business, a leading Contract Development and Manufacturing Organization (CDMO), announced that the company's site in Pithampur, Madhya Pradesh, India, has been selected as the winner of the most recent PPS Award for Excellence in Patient Centricity. The Pithampur Patient Awareness Council (PAC) was recognized for the program entitled "Imbibing Patient Centricity in All Strata, Internally & Externally."



This award, which is given out twice per year, goes to the Patient Awareness Council (PAC) at a PPS site in recognition of a specific program they initiated related to Patient Centricity. A core ideology of the company, Patient Centricity is built upon the principal that understanding the needs of patients and building an organization that is dedicated to addressing those needs is foundational to the company. As part of the Patient Centricity onboarding initiative, employees at all

fourteen of the company's sites around the world received dedicated training on how to embrace the concept and make the program a reality. Patient Awareness Councils were formed at each site for the purpose of driving the idea forward at a local level.



According to **Stuart Needleman, Chief Patient Centricity Officer at Piramal Pharma Solutions**, “Over the past 6 months, our site PACs came through with a collection of thoughtful and powerful initiatives to drive patient centricity at their site. Unfortunately, there can only be one winner, but we are pleased with our decision to present the award to the Pithampur PAC. Their program did a great job of extending our message of patient centricity outside the organization, to partners and other stakeholders who work with the site. It was clearly aligned with our ethos of patient centricity.”

The Pithampur PAC’s program was designed to create a cultural shift by applying patient centricity as an elevation lever. Emphasis was placed on instilling a patient-centric mind set across the production area, to shop floor workers and machine operators, reminding them to take special care, since they are producing drug product that patients rely on. The program brought the concept into all strata at the site – into its very DNA – by extending the concept beyond the technical and operational staffs. Support workers, including transporters, security staff, canteen staff members, civil workers, gardeners, housekeeping partners, and others, were educated on how their roles are also part of a patient-centric culture. In a similar fashion, the initiative reached external partners, including doctors, community pharmacists, students, health care professionals, and customers who have ongoing programs at the site.



**Peter DeYoung, Chief Executive Officer, Piramal Pharma Solutions** said, “Each year, in conjunction with the WHO’s Patient Safety Day, we celebrate Patient Centricity Week across all our global sites. We see a clear connection between our efforts to be patient centric and the WHO’s mission to recognize patient safety through global solidarity and united action. The Excellence in Patient Centricity Award validates that connection by recognizing one site’s efforts to improve the lives of patients. Congratulations to the Pithampur PAC for this award and for their dedication to our ethos of patient centricity.”

\*\*\*

**About Piramal Pharma Solutions:**

Piramal Pharma Solutions (PPS) is a Contract Development and Manufacturing Organization (CDMO) offering end-to-end development and manufacturing solutions across the drug life cycle. We serve our customers through a globally integrated network of facilities in North America, Europe, and Asia. This enables us to offer a comprehensive range of services including drug discovery solutions, process & pharmaceutical development services, clinical trial supplies, commercial supply of APIs, and finished dosage forms. We also offer specialized services such as the development and manufacture of highly potent APIs, antibody-drug conjugations, sterile fill/finish, peptide products & services, and potent solid oral drug product. PPS also offers development and manufacturing services for biologics including vaccines, gene therapies, and monoclonal antibodies, made possible through Piramal Pharma Limited's investment in Yapan Bio Private Limited. Our track record as a trusted service provider with experience across varied technologies makes us a partner of choice for innovator and generic companies worldwide. For more information please visit: [www.piramalpharmasolutions.com](http://www.piramalpharmasolutions.com) | [Twitter](#) | [LinkedIn](#)

**About Piramal Pharma Ltd:**

Piramal Pharma Limited (PPL, NSE: PPLPHARMA | BSE: 543635), a leading global pharmaceuticals company, offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 15 global facilities and a distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated Contract Development and Manufacturing Organization; Piramal Critical Care (PCC), a Complex Hospital Generics business, and the India Consumer Healthcare business selling over-the-counter products. PPS offers end-to-end development and manufacturing solutions through a globally integrated network of facilities across the drug life cycle to innovators and generic companies. PCC's complex hospital product portfolio includes inhalation anaesthetics, intrathecal therapies for spasticity and pain management, injectable pain and anaesthetics, injectable anti-infectives, and other therapies. The Indian Consumer Healthcare business is among the leading players in India in the self-care space, with established brands in the Indian consumer healthcare market. In addition, PPL has a joint venture with Allergan, a leader in ophthalmology in the Indian formulations market. In October 2020, the company received a growth equity investment from the Carlyle Group. For more information visit: [www.piramal.com/pharma/](http://www.piramal.com/pharma/) | [Facebook](#) | [Twitter](#) | [LinkedIn](#)

---

**For Media Queries:**

Rajiv Banerjee  
Corporate Communications  
[Rajiv.Banerjee@piramal.com](mailto:Rajiv.Banerjee@piramal.com)

**For Investors:**

Gagan Borana  
Investor Relations  
[Gagan.Borana@piramal.com](mailto:Gagan.Borana@piramal.com)